News

Q&A: A New Treatment Approved for Certain Brain Tumors In late June 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The approved combination of two oral drugs, called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist), is for the treatment of advanced tumors […] August 9, 2022

New Brain Tumor Clinical Trials: January – June 2022 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the […] July 5, 2022

New Treatment Approved for Certain Glioma Patients On June 22, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The FDA approved the combination of two oral drugs called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist) for the treatment of advanced tumors […] June 28, 2022

National Brain Tumor Society Statement on New Biden-Harris Cancer Moonshot Goals National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, was honored to represent the millions of Americans impacted by brain tumors every year at a White House event to reignite the Cancer Moonshot.  The following is a statement from NBTS chief executive officer, David Arons, on today’s announcement. […] February 2, 2022

NBTS Brain Tumor Clinical Trials Report: Q4 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started […] January 13, 2022